<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02223065</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-364</org_study_id>
    <nct_id>NCT02223065</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State</brief_title>
  <official_title>A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate bioequivalence of coadministered drugs on healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saxagliptin Maximum Observed Concentrations (Cmax)</measure>
    <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
    <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin Maximum Observed Concentrations (Cmax)</measure>
    <time_frame>Day 1 to 3 (Period 1) and Day 8 to 10 (Period 2)</time_frame>
    <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])</measure>
    <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
    <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])</measure>
    <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
    <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</measure>
    <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
    <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</measure>
    <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
    <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of FDC (fixed-dose combination) tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Farxiga in the United States</other_name>
    <other_name>Forxiga in other countries</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form

               -  Signed written informed consent must be obtained from the subjects in accordance
                  with requirements of the study center's IRB or IEC before the initiation of any
                  protocol-required procedures.

          2. Target Population

               -  Healthy subjects as determined by no clinically significant deviation from normal
                  in medical history, psychiatric history, physical examination findings, vital
                  sign measurements, 12-lead ECG measurements, physical measurements, and clinical
                  laboratory test results.

          3. Age and Reproductive Status

               -  Males and females, ages 19 to 55 years, inclusive. To extent possible, the
                  distribution of men and women between the sequences will be balanced

               -  Women of childbearing potential (WOCBP) must have a negative serum or urine
                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24
                  hours prior to the start of study drug.

               -  Women must not be breastfeeding. d) WOCBP must agree to follow instructions for
                  method(s) of contraception for the duration of treatment with study drugs
                  saxagliptin and dapagliflozin plus 5 half lives of study drug dapagliflozin (the
                  longer half life between the 2 drugs; 3 days) for a total of 3 days following
                  treatment completion.

                  e) Men who are sexually active with WOCBP must agree to follow instructions for
                  method(s) of contraception for the duration of treatment with study drugs
                  saxagliptin and dapagliflozin plus 5 half lives of dapagliflozin (the longer half
                  life between the 2 drugs; 3 days) for a total of 3 days following treatment
                  completion.

                  f) Azoospermic males and WOCBP who are continuously not heterosexually active are
                  exempt from contraceptive requirements. However, they must still undergo
                  pregnancy testing as described in this section

             Exclusion Criteria:

               -  Any significant acute or chronic medical illness.

               -  Current or recent (within 3 months of study drug administration) gastrointestinal
                  disease that could impact upon the absorption of study drug

               -  Any other sound medical, psychiatric, and/or social reason as determined by the
                  investigator

               -  Any major surgery within 4 weeks of study drug administration.

               -  Any prior GI surgery including cholecystectomy (remote history of appendectomy
                  will not be exclusionary).

               -  Current, recent (within 3 months of study drug administration), or remote history
                  of pancreatitis.

               -  Donation of blood or plasma to a blood bank or in a clinical study (except at
                  screening visit) within 4 weeks before study drug administration.

               -  Blood transfusion within 4 weeks of study drug administration. h) Inability to
                  tolerate oral medication.

               -  Inability to be venipunctured performed and/or tolerate venous access.

               -  Use of tobacco- or nicotine-containing products (including, but not limited to,
                  cigarettes, pipes, e-cigarettes, cigars, chewing tobacco, nicotine patches,
                  nicotine lozenges, or nicotine gum) within 6 months before check-in.

               -  Drug or alcohol abuse (within 2 years of study drug administration) as defined in
                  the Diagnostic and Statistical Manual of Mental Disorders - 4th Edition,
                  Diagnostic Criteria for Drug and Alcohol Abuse History of glucose intolerance or
                  diabetes mellitus.

               -  For females, history of chronic or recurrent urinary tract infection (UTI)
                  (defined as 3 occurrences per year) or UTI in the past 3 months. For males, any
                  UTI within the previous 5 years that has not been thoroughly evaluated and for
                  which an explanation is not clear.

               -  History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal
                  mycotic infections.

               -  Any other sound medical, psychiatric, and/or social reason as determined by the
                  investigator.

             Physical and Laboratory Test Findings

               1. Evidence of organ dysfunction or any clinically significant deviation from normal
                  in physical examination, vital signs, ECGs, or clinical laboratory determinations
                  beyond what is consistent with the target population.

               2. Abnormal urinalysis at screening (may repeat once). If the urinalysis is abnormal
                  on Day -1 of Period 1, continuation in the study is up to the investigator's
                  discretion. The CRO medical monitor should be consulted.

               3. Glucosuria or hematoria at screening or Day -1 of Period 1, repeat is not
                  permitted. d) A positive nicotine test (ie, cotinine).

             e) Abnormal liver function tests (alanine or aspartate aminotransferase [ALT or AST,
             respectively], or total bilirubin).

             f) Any of the following on 12-lead ECG prior to study drug administration, confirmed
             by repeat.

             i) PR ≥ 210 ms ii) QRS ≥ 120 ms iii) QT ≥ 500 ms iv) QTcF ≥ 450 ms g) Positive urine
             screen for drugs of abuse. h) Positive urine alcohol test. i) Positive blood screen
             for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human
             immunodeficiency virus (HIV)-1 or HIV-2 antibodies at screening.

          4. Allergies and Adverse Drug Reaction

               1. History of allergy or adverse reactions to DPP4 or SGLT inhibitors or related
                  compounds.

               2. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity).

          5. Other Exclusion Criteria

               1. Prisoners or subjects who are involuntarily incarcerated.

               2. Subjects who are compulsorily detained for treatment of either a psychiatric or
                  physical (eg, infectious disease) illness.

               3. Inability to comply with restrictions and prohibited activities/treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gartner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <results_first_submitted>February 17, 2016</results_first_submitted>
  <results_first_submitted_qc>March 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2016</results_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Open-label, randomized, single-dose, 2-treatment, 2-period crossover study in 36 healthy subjects. A single dose was administered on Day 1 and Day 8 under fasted conditions. Blood samples for the plasma pharmacokinetic analysis collected over a 60-hour interval after dosing in each period</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment AB</title>
          <description>Treatment A: Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.
Treatment B: Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>Treatment BA</title>
          <description>Treatment B: Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.
Treatment A: Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment AB</title>
          <description>Treatment A: Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.
Treatment B: Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
        </group>
        <group group_id="B2">
          <title>Treatment BA</title>
          <description>Treatment B: Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.
Treatment A: Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="11.63" lower_limit="19" upper_limit="53"/>
                    <measurement group_id="B2" value="32.9" spread="11.34" lower_limit="19" upper_limit="52"/>
                    <measurement group_id="B3" value="33.3" spread="11.32" lower_limit="19" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>BLACK/AFRICAN AMERICAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHITE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin Maximum Observed Concentrations (Cmax)</title>
        <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
        <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
        <population>Evaluable PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Maximum Observed Concentrations (Cmax)</title>
          <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
          <population>Evaluable PK Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="5.723" lower_limit="24.6" upper_limit="27.8"/>
                    <measurement group_id="O2" value="25.5" spread="5.763" lower_limit="24.0" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified bioequivalence limits (0.80, 1.25) for PK measures</non_inferiority_desc>
            <p_value>0.4950</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.975</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.915</ci_lower_limit>
            <ci_upper_limit>1.038</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin Maximum Observed Concentrations (Cmax)</title>
        <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
        <time_frame>Day 1 to 3 (Period 1) and Day 8 to 10 (Period 2)</time_frame>
        <population>Evaluable PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin Maximum Observed Concentrations (Cmax)</title>
          <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
          <population>Evaluable PK Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" spread="28.93" lower_limit="132" upper_limit="153"/>
                    <measurement group_id="O2" value="141" spread="37.10" lower_limit="132" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified bioequivalence limits (0.80, 1.25) for PK measures</non_inferiority_desc>
            <p_value>0.8650</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.993</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.932</ci_lower_limit>
            <ci_upper_limit>1.060</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])</title>
        <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
        <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
        <population>Evaluable PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])</title>
          <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
          <population>Evaluable PK Population</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="5.723" lower_limit="90.0" upper_limit="102"/>
                    <measurement group_id="O2" value="98.0" spread="5.763" lower_limit="92.0" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified bioequivalence limits (0.80, 1.25) for PK measures</non_inferiority_desc>
            <p_value>0.2344</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.022</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.991</ci_lower_limit>
            <ci_upper_limit>1.054</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])</title>
        <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
        <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
        <population>Evaluable PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])</title>
          <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
          <population>Evaluable PK Population</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537" spread="5.723" lower_limit="504" upper_limit="573"/>
                    <measurement group_id="O2" value="546" spread="5.763" lower_limit="512" upper_limit="582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified bioequivalence limits (0.80, 1.25) for PK measures</non_inferiority_desc>
            <p_value>0.2458</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.016</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.993</ci_lower_limit>
            <ci_upper_limit>1.038</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</title>
        <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
        <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
        <population>Evaluable PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</title>
          <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
          <population>Evaluable PK Population</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" spread="5.723" lower_limit="91.1" upper_limit="103"/>
                    <measurement group_id="O2" value="99.4" spread="5.763" lower_limit="93.3" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified bioequivalence limits (0.80, 1.25) for PK measures</non_inferiority_desc>
            <p_value>0.1947</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.024</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.993</ci_lower_limit>
            <ci_upper_limit>1.056</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</title>
        <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
        <time_frame>Day 1-3 (Period 1) and Day 8-10 (Period 2)</time_frame>
        <population>Evaluable PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</title>
          <description>5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state</description>
          <population>Evaluable PK Population</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553" spread="5.723" lower_limit="518" upper_limit="591"/>
                    <measurement group_id="O2" value="561" spread="5.763" lower_limit="525" upper_limit="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified bioequivalence limits (0.80, 1.25) for PK measures</non_inferiority_desc>
            <p_value>0.3191</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.013</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.992</ci_lower_limit>
            <ci_upper_limit>1.034</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Single oral dose of 5-mg saxagliptin tablet coadministered with 10-mg dapagliflozin tablet under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Single oral dose of 5-mg saxagliptin/10-mg dapagliflozin FDC tablet under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eva Johnsson, Clinical Science Lead, GLOBAL_MEDICINES_DEV</name_or_title>
      <organization>AstraZeneca AB, S-151 85 Södertälje, Sweden</organization>
      <phone>+46 31 7762484 ext 762 484</phone>
      <email>Eva.Johnsson@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

